Investors like comparing stocks on a sector-wide basis, but sometimes it's hard to know which sector a stock belongs in. In the case of Danaher Corporation (DHR 0.53%), the company was previously categorized as an industrial company with a heavy medical focus, but following the separation of Fortive Corp (FTV 0.41%) it's more accurate to think of it as a medical technology-focused company with some industrial exposure. Ultimately, I think that means the stock deserves a positive rerating. Here's why.

man looking at money through binoculars

Image source: Getty Images

A new Danaher

The separation of Fortive removed the professional instrumentation and industrial technologies businesses and left Danaher as a medically focused company. Fortive is a highly investable company in its own right, offering investors exposure to the cyclicality of the industrial sector -- the peer group that Danaher was traditionally compared to.

However, as you can see below, the new Danaher's end market mix is now primarily focused on relatively non-cyclical end markets, such as life sciences, diagnostics, dental and environmental products.

danaher 2016 revenue split by segment

Data source: Danaher Corporation presentations.

In this case, if you start thinking about Danaher as a life sciences and diagnostics technology company, then the stock starts to look relatively cheap compared to its peers across a raft of metrics, although it's expensive when compared to the industrial sector.

DHR EV to EBITDA (Forward) Chart

DHR EV to EBITDA (Forward) data by YCharts

Less cyclical earnings

One of the reasons why the life sciences & diagnostics sector is seen as deserving a higher rating is its less cyclical nature. This is confirmed when looking at changes in revenue between 2008-2009 for Danaher's segments at the time. In the following chart, I've grouped together Danaher's revenue in the three segments most closely aligned with the current Danaher and separated them from the industrial business which are, for the most part, within Fortive now.

As you can see below, the combined revenue from life sciences & diagnostics, environmental, and dental fell much less during the recession in 2009 than the highly cyclical industrial businesses -- in fact, life sciences & diagnostics and environmental actually rose 0.2%.

a breakout of change in revenue for Danaher between 2008 and 2009

Data source: Danaher Corporation presentations.

All told, the new Danaher's revenue is a lot less exposed to the economic cycle than the old Danaher was, which goes even further to suggest the stock deserves a positive rerating.

Consumables will help too

In addition to its end markets being less cyclical, the nature of Danaher's revenue is as well. For example, on the company's investor and analyst meeting in December, management outlined that 65% of its total revenue now came from consumables.

This is good for three key reasons:

  • It reduces cyclicality, as consumables tend to produce a more reliable income stream than equipment sales do -- companies tend to stop buying equipment during a slowdown.
  • Stronger relationships with customers as they keep buying Danaher's consumables on an ongoing basis.
  • Consumables tend to come with higher margins and higher cash flow generation.

High free-cash flow generation

As outlined above, the high percentage of consumables sales in Danaher's revenue tends to mean the company generates a lot of free-cash flow (FCF) from net income. The chart below shows FCF to net income during the last four years -- and the average is an impressive 125%.

Danaher's free cash flow to net income

Data source: Danaher Corporation presentations. FCF and net income are from continuing operations only

It's reasonable to expect this figure to increase in the future, particularly as management integrates and grows revenue in diagnostics with Cepheid, an acquired business that earns around 75% of its revenue from consumables, and Pall Corp, which also makes around 75% of its revenue from consumables.

Danaher Corporation deserves a rerating

All told, Danaher isn't really an industrial company anymore. Based on the relative valuations show above, and the change in nature of its earnings and FCF generation, I would argue that it deserves a rerating in-line with its life sciences and diagnostics peers.